The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer.
B. Massuti
No relevant relationships to disclose
U. Jimenez
No relevant relationships to disclose
J. M. Rodriguez Paniagua
No relevant relationships to disclose
Y. W. Pun
No relevant relationships to disclose
M. Cobo
No relevant relationships to disclose
E. Carcereny Costa
No relevant relationships to disclose
R. Arrabal
No relevant relationships to disclose
J. Astudillo
No relevant relationships to disclose
I. C. Barneto
No relevant relationships to disclose
R. De Las Penas
No relevant relationships to disclose
C. Baamonde
No relevant relationships to disclose
G. Sales
No relevant relationships to disclose
J. Gonzalez-Larriba
No relevant relationships to disclose
G. Lopez-Vivanco
No relevant relationships to disclose
F. Hernando-Trancho
No relevant relationships to disclose
J. Pac
No relevant relationships to disclose
A. Artal-Cortes
No relevant relationships to disclose
J. Rivas
No relevant relationships to disclose
R. Rosell
Consultant or Advisory Role - Sanofi
J. M. Sanchez
No relevant relationships to disclose